Kepler Capital Remains a Buy on Sandvik AB (0HC0)
Kepler Capital analyst Johan Sjoberg maintained a Buy rating on Sandvik AB (0HC0 – Research Report) on May 15 and set a price target of SEK250.00. The company's shares closed last Thursday at SEK217.70.
Confident Investing Starts Here:
Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Sjoberg is a 3-star analyst with an average return of 2.1% and a 57.35% success rate.
In addition to Kepler Capital , Sandvik AB also received a Buy from Morgan Stanley's Michael Harleaux in a report issued on May 12. However, on May 13, UBS maintained a Sell rating on Sandvik AB (LSE: 0HC0).
Based on Sandvik AB's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of SEK29.3 billion and a net profit of SEK3.74 billion. In comparison, last year the company earned a revenue of SEK29 billion and had a net profit of SEK1.25 billion
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
3 Promising UK Penny Stocks With Market Caps Over £50M
The UK market has recently faced challenges, with the FTSE 100 index faltering due to weak trade data from China, highlighting global economic interdependencies. Despite these broader market pressures, certain investment opportunities remain attractive. Penny stocks, although an outdated term, continue to represent smaller or less-established companies that can offer value and growth potential when backed by strong financials. In this article, we will explore three such UK penny stocks that stand out for their financial health and potential for future growth. Name Share Price Market Cap Financial Health Rating Foresight Group Holdings (LSE:FSG) £3.96 £445.67M ★★★★★★ Warpaint London (AIM:W7L) £4.55 £367.58M ★★★★★★ Cairn Homes (LSE:CRN) £1.86 £1.16B ★★★★★☆ Van Elle Holdings (AIM:VANL) £0.365 £39.49M ★★★★★★ Helios Underwriting (AIM:HUW) £2.34 £169.52M ★★★★★☆ Polar Capital Holdings (AIM:POLR) £4.345 £418.91M ★★★★★★ LSL Property Services (LSE:LSL) £2.88 £297.56M ★★★★★☆ Begbies Traynor Group (AIM:BEG) £1.04 £165.92M ★★★★★★ Croma Security Solutions Group (AIM:CSSG) £0.86 £11.84M ★★★★★★ Braemar (LSE:BMS) £2.31 £72.32M ★★★★★★ Click here to see the full list of 401 stocks from our UK Penny Stocks screener. Let's take a closer look at a couple of our picks from the screened companies. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Iofina plc, with a market cap of £50.27 million, explores, develops, and produces iodine and halogen-based specialty chemical derivatives from oil and gas operations in the United States and the United Kingdom. Operations: The company's revenue is primarily generated from halogen derivatives and iodine, amounting to $54.47 million. Market Cap: £50.27M Iofina plc, with a market cap of £50.27 million, is positioned within the penny stock segment due to its valuation and operational scale. The company reported revenue of US$54.47 million for 2024, showing modest growth from the previous year but faced a decline in net income to US$2.92 million from US$6.56 million. Despite stable weekly volatility and high-quality earnings, Iofina's profit margins have decreased significantly over the past year, and it lowered its iodine production guidance for early 2025. However, strong asset coverage and reduced debt levels enhance its financial resilience amidst these challenges. Jump into the full analysis health report here for a deeper understanding of Iofina. Evaluate Iofina's prospects by accessing our earnings growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Ramsdens Holdings PLC provides diversified financial services both in the United Kingdom and internationally, with a market capitalization of £112.70 million. Operations: Ramsdens Holdings PLC does not report specific revenue segments. Market Cap: £112.7M Ramsdens Holdings PLC, with a market cap of £112.70 million, demonstrates robust financial health within the penny stock category. The company reported half-year sales of £51.6 million and net income of £4.43 million, up from the previous year, indicating strong earnings growth. Its seasoned management team has overseen an increase in net profit margins and a stable debt profile supported by more cash than total debt. Recent announcements include plans to expand store openings and an increased interim dividend by 25% to 4.5 pence per share, highlighting its commitment to shareholder returns amidst ongoing business expansion efforts. Take a closer look at Ramsdens Holdings' potential here in our financial health report. Understand Ramsdens Holdings' earnings outlook by examining our growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Focusrite plc develops, manufactures, and markets professional audio and electronic music products globally, with a market cap of £105.52 million. Operations: The company's revenue is derived from various segments, including Focusrite (£61.79 million), Novation (£17.07 million), ADAM Audio (£24.972 million), Martin Audio (£46.38 million), Sequential (£10.418 million), and Sonnox (£1.917 million). Market Cap: £105.52M Focusrite plc, with a market cap of £105.52 million, shows mixed signals in the penny stock arena. While earnings are forecast to grow at 35% annually, recent net profit margins have declined from 7% to 1.2%. The company's revenue for the first half of 2025 increased to £80.91 million from £76.88 million a year prior, but net income decreased to £1.84 million from £2.47 million. Despite high volatility and low return on equity (1.7%), Focusrite maintains satisfactory debt levels and strong short-term asset coverage over liabilities, supporting its financial stability amidst fluctuating performance metrics. Dive into the specifics of Focusrite here with our thorough balance sheet health report. Learn about Focusrite's future growth trajectory here. Investigate our full lineup of 401 UK Penny Stocks right here. Interested In Other Possibilities? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 24 best rare earth metal stocks of the very few that mine this essential strategic resource. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AIM:IOF AIM:RFX and AIM:TUNE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 hours ago
- Business Insider
PROCEPT BioRobotics (PRCT) Gets a Buy from TD Cowen
In a report released yesterday, Josh Jennings from TD Cowen reiterated a Buy rating on PROCEPT BioRobotics (PRCT – Research Report). The company's shares closed yesterday at $65.05. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Jennings covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Medtronic, and Establishment Labs Holdings. According to TipRanks, Jennings has an average return of 4.6% and a 52.11% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for PROCEPT BioRobotics with a $80.20 average price target. PRCT market cap is currently $3.32B and has a P/E ratio of -36.24. Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PRCT in relation to earlier this year. Most recently, in March 2025, Reza Zadno, the President & CEO of PRCT sold 5,475.00 shares for a total of $312,403.50.
Business Insider
2 hours ago
- Business Insider
Stifel Nicolaus Keeps Their Buy Rating on Kymera Therapeutics (KYMR)
analyst Alex Thompson CFA maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report) yesterday and set a price target of $68.00. The company's shares closed yesterday at $47.66. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Thompson CFA covers the Healthcare sector, focusing on stocks such as Kymera Therapeutics, Oruka Therapeutics, and Travere Therapeutics. According to TipRanks, Thompson CFA has an average return of -2.8% and a 45.45% success rate on recommended stocks. In addition to Stifel Nicolaus, Kymera Therapeutics also received a Buy from UBS's Eliana Merle in a report issued on June 3. However, on May 30, Bank of America Securities maintained a Hold rating on Kymera Therapeutics (NASDAQ: KYMR). The company has a one-year high of $53.27 and a one-year low of $19.45. Currently, Kymera Therapeutics has an average volume of 856.8K.
